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Abstract
Since chemotherapy began as a treatment for cancer in the 1940s, cancer drug development has
become a multi-billion dollar industry. Combination chemotherapy remains the leading treatment
for advanced cancers, and cancer drug research and clinical trials are enormous expenses for phar-
maceutical companies and the government. We propose an analytics approach for the analysis
and design of clinical trials that can discover drug combinations with significant improvements in
survival and toxicity. We first build a comprehensive database of clinical trials. We then use this
database to develop statistical models from earlier trials that are capable of predicting the survival
and toxicity of new combinations of drugs. Then, using these statistical models, we develop opti-
mization models that select novel treatment regimens that could be tested in clinical trials, based
on the totality of data available on existing combinations. We present evidence for advanced gastric
and gastroesophageal cancers that the proposed analytics approach a) leads to accurate predictions
of survival and toxicity outcomes of clinical trials as long as the drugs used have been seen before
in different combinations, b) suggests novel treatment regimens that balance survival and toxicity
and take into account the uncertainty in our predictions, and c) outperforms the trials run by
the average oncologist to give survival improvements of several months. Ultimately, our analytics
approach offers promise for improving life expectancy and quality of life for cancer patients at low
cost.
Thesis Supervisor: Dimitris J. Bertsimas
Title: Boeing Professor of Operations Research
Co-Director, Operations Research Center
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Chapter 1
Introduction
Cancer is a leading cause of death worldwide, accounting for 7.6 million deaths in 2008. This
number is projected to continue rising, with an estimated 13.1 million deaths in 2030 (World Health
Organization 2012). The prognosis for many advanced cancers is grim unless they are caught at an
early stage, when the tumor is contained and can still be surgically removed. Often, at the time of
diagnosis, the cancer is sufficiently advanced that it has metastasized to other organs and can no
longer be surgically removed, leaving chemotherapy and radiation as the only treatment options.
Since chemotherapy began as a treatment for cancer in the 1940s, cancer drug development
has become a multi-billion dollar industry. For instance, Avastin alone generated $2.9 billion in
revenues for Genentech in 2008. Though most improvements in the effectiveness of chemotherapy
treatments have come from new drug development, one of the largest breakthroughs in cancer treat-
ment occurred in 1965, when a team of researchers suggested the idea of combination chemother-
apy (Chabner and Roberts 2005). Today, most successful chemotherapy treatments for advanced
cancers use multiple drugs simultaneously; specifically, in this work we found that nearly 80%
of all chemotherapy clinical trials for advanced gastric and gastroesophageal cancers have tested
combined treatments.
Finding effective new combination chemotherapy treatments is challenging — there are a huge
number of potential drug combinations, especially when considering different dosages and dosing
schedules for each drug. There are some generally accepted guidelines for selecting drug combina-
tions, such as selecting drugs that are known to be active as single agents, and combining drugs
with different mechanisms of action (Page and Takimoto 2002, Pratt 1994, Golan et al. 2008).
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While these serve as guidelines to clinical trial decision makers, there are still a large number of
feasible combinations. In our approach, we adhere to these guidelines while optimizing over drug
combinations.
Trials are also expensive, with average costs in many cases exceeding $10, 000 per patient
enrolled (Emanuel et al. 2003); these costs are often incurred either by pharmaceutical companies
or the government. Further, comparing clinical trial results is complicated by the fact that the trials
are run with different patient populations; establishing one regimen as superior to another involves
running a large randomized study, at a cost of millions of dollars. In this work, we develop low-cost
techniques for suggesting new treatment combinations and for comparing results from trials with
different patient populations.
Our aspiration in this work is to propose an analytics approach for the analysis and design of
clinical trials that provides insights into what is the best currently available drug combination to
treat a particular form of cancer and how to design new clinical trials that can discover improved
drug combinations. The key contributions of the thesis are:
(1) We developed a database for advanced gastric and gastroesophageal cancers from papers
published in the period 1979-2012. Surprisingly and to the best of our knowledge, such a database
did not exist prior to this study.
(2) We construct statistical models trained on previous randomized and single-arm clinical
trials to predict the outcomes of clinical trials (survival and toxicity) before they are run, when
the trials’ drugs have been tested before but in different combinations. One of the most important
findings of this research is that the survival and toxicity outcomes of clinical trials can to a large
extent be predicted in advance (R2 = 0.60 for out-of-sample survival predictions, AUC = 0.84 for
predicting high toxicity), as long as the drugs used have been seen before in different combinations.
(3) We provide evidence that our analytics based methods a) identify clinical trials that are
unlikely to succeed, thus avoiding low-quality experiments, saving money and time and extending
patients’ lives and b) determine best treatments to date taking into account toxicity and survival
tradeoffs as well as patient demographics, thus enabling doctor and patients to make more informed
decisions regarding best available treatments.
(4) Perhaps most importantly, we propose an optimization-based methodology of suggesting
novel treatment regimens that balances survival and toxicity and takes into account the uncertainty
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in our predictions. We demonstrate that the proposed approach can quickly identify promising
combinations of drugs, speeding the process of medical discovery. Specifically, we make proposals
for promising trials that have been performed years later that have significantly better outcomes
than the average trial.
Overall, we feel that this work provides evidence that analytics, that is the combination of
data, statistical models and optimization, can offer insights on which are the best treatments today
and open new frontiers in the design of promising clinical trials in the future. While the results
presented here are for a specific form of cancer (gastric and gastroesophageal), the methodology is
widely applicable for other forms of cancer.
Medical practitioners have a rich history of predicting clinical outcomes through the field of
medical prognosis. For instance, techniques for prediction of patient survival range from simple
approaches like logistic regression to more sophisticated ones such as artificial neural networks
and decision trees (Ohno-Machado 2001). Most commonly, these prediction models are trained
on individual patient records and used to predict the clinical outcome of an unseen patient, of-
ten yielding impressive out-of-sample predictions (Burke 1997, Delen 2005, Jefferson et al. 1997).
Areas of particular promise involve incorporating biomarker and genetic information into individ-
ualized chemotherapy outcome predictions (Efferth and Volm 2005, Phan et al. 2009). Though
individualized predictions represent a useful tool to patients seeking treatment, they do not en-
able predictions of outcomes for patients treated with previously unseen chemotherapy regimens,
limiting their usefulness in planning new clinical trials.
The field of meta-regression involves building models of clinical trial outcomes such as patient
survival or toxicities, trained on patient demographics and trial drug information. These regressions
are used to complement meta-analyses, explaining statistical heterogeneity between the effect sizes
computed from randomized clinical trials (Thompson and Higgins 2002). Though in structure
meta-regressions are identical to the prediction models we build, representing trial outcomes as a
function of trial properties, to date they have mainly been used as tools to explain differences in
existing randomized trials, and evaluations of the predictiveness of the regression models are not
performed. Like meta-analyses, meta-regressions are performed on a small subset of the clinical
trials for a given disease, often containing just a few drug combinations. Even when a wide range
of drug combinations are considered, meta-regressions typically do not contain enough drug-related
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variables to be useful in proposing new trials. For instance, Hsu et al. (2012) predicts 1-year overall
survival using only three variables to describe the drug combination in the clinical trial; new
combination chemotherapy trials could not be proposed using the results of this meta-regression.
To the best of our knowledge, this work presents the first prediction model to date that contains
enough detail about the drug combination and dosages used in a clinical trial to enable planning
for future combination chemotherapy trials. We attain this by significantly broadening the scope
of meta-regression, training our model not only on randomized clinical trials but also on single-arm
trials for a given form of cancer and performing out-of-sample validation of the predictions returned.
This model enables us to propose new combination chemotherapy clinical trials via optimization.
To our knowledge this is a new approach to the design of clinical trials, an important problem
facing the pharmaceutical industry, the government, and the healthcare industry.
Throughout the thesis, we focus on gastric and gastroesophageal cancers. Not only are these
cancers very important — gastric cancer is the second leading cause of cancer death in the world
and esophageal cancer is the sixth (Jemal et al. 2011) — but there is no single chemotherapy
regimen widely considered to be the standard or best treatment for these cancers (Wagner 2006,
Wong and Cunningham 2009, NCCN 2013).
This thesis is structured as follows. In Section 2, we describe our data collection, including how
we built a database of clinical trial results for gastric and gastroesophageal cancers. In Section 3,
we describe our statistical models to predict the outcomes of clinical trials. In Section 4, we propose
optimization models to improve the design of clinical trials. In Section 5, we present additional
applications of our statistical models to identify clinical trials that are unlikely to succeed and
determine the best known treatments to date. Lastly, in Section 6, we provide some concluding
remarks.
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Chapter 2
Data Collection
To train statistical models to predict the results of unseen clinical trials, we first built a database
of existing clinical trials for advanced and metastatic gastric and gastroesophageal cancers.
2.1 Inclusion and Exclusion Criteria
In this study, we seek to include a wide range of clinical trials, subject to the following inclusion
criteria: (1) Phase I/II, Phase II or Phase III clinical trials for metastatic gastric or gastroesophageal
cancer, (2) trials published no later than March 2012, the study cutoff date, (3) trials published in
the English language. Notably, these criteria include non-randomized clinical trials; all published
meta-analyses we are aware of for gastric cancer (e.g. Hermans (1993), Earle and Maroun (1999),
Mari (2000), Wagner (2006)) are limited to randomized controlled trials, in which patients are
randomly assigned to one of several arms in the trial. While including non-randomized trials
provides us with a significantly larger set of clinical trial outcomes and the ability to generate
predictions for a broader range of chemotherapy drug combinations, this comes at the price of
needing to control for differences in demographics and other factors between different clinical trials.
Exclusion criteria were: (1) sequential trials, (2) trials that involve the application of radi-
ation therapy,1 (3) trials that apply curative or adjuvant chemotherapy, and (4) trials to treat
gastrointestinal stromal tumors.
1Radiotherapy is not recommended for metastatic gastric cancer patients (NCCN 2013), and through PubMed
and Cochrane searches for stomach neoplasms and radiotherapy, we only found three clinical trials using radiotherapy
for metastatic gastric cancer.
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2.2 Data Sources and Queries
To locate candidate papers for our database, we performed searches on PubMed, the Cochrane
Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews. In
the Cochrane systems, we searched for either MESH term “Stomach Neoplasms” or MESH term
“Esophageal Neoplasms” with the qualifier “Drug Therapy.” In PubMed, we searched for “gastr*”
or “stomach” in the title and “advanced” or “metastatic” in the title and “phase” or “randomized
trial” or “randomised trial” in the title. These searches yielded 350 papers that met the inclusion
criteria for this study.
After this search through databases of clinical trial papers, we further expanded our set of
papers by searching through the references of papers that met our inclusion criteria. This reference
search yielded 56 additional papers that met the inclusion criteria for this study. In total, our
systematic literature review yielded 406 papers for gastric cancer that we deemed appropriate for
our approach. Since there are often multiple papers published regarding the same clinical trial, we
verified that each clinical trial included was unique.
2.3 Manual Data Collection
We manually extracted data from clinical trials, and extracted data values were inputted into a
database. Values not reported in the clinical trial report were marked as such in the database.
For each drug in a given trial’s chemotherapy treatment, the drug name, dosage level for each
application, number of applications per cycle, and cycle length were collected. We also extracted
many covariates that have been previously investigated for their effects on response rate or overall
survival in prior chemotherapy clinical trials for advanced gastric cancer. To limit bias associated
with missing information about a clinical trial, we limited ourselves to variables that are widely
reported in clinical trials. These variables are summarized in Table 2.1. We chose not to collect
many less commonly reported covariates that have also been investigated for their effects on response
and survival, including cancer extent, histology, a patient’s history of prior adjuvant therapy and
surgery, and further details of patients’ initial conditions, such as their baseline bilirubin levels or
body surface areas (Ajani et al. 2010, Bang et al. 2010, Kang et al. 2009, Koizumi et al. 2008).
We extracted clinical trial outcome measures of interest that capture the efficacy and toxicity
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of each treatment. Several measures of treatment efficacy (e.g. tumor response rate, time until
tumor progression, survival time) are commonly reported in clinical trials. A review of the primary
objectives of the Phase III trials in our database indicated that for the majority of these trials
(62%), the primary objective was to demonstrate improvement in terms of the median overall
survival (OS) of patients in the treatment group. As a result, this is the metric we have chosen as
our measure of efficacy.2 To capture the toxic effects of treatment, we also extracted the fraction
of patients experiencing any toxicity at Grade 3/4 or Grade 4, designating severe, life-threatening,
or disabling toxicities (National Cancer Institute 2006).
In Table 2.1, we record the patient demographics we collected as well as trial outcomes. We
note that the set of toxicities reported varies across trials, and that the database contains a total
of 7,360 toxicity entries, averaging 15 reported toxicities per trial arm. In Section 2.4 below, we
present a method for combining this toxicity data into a single score representative of the overall
toxicity of each trial.
2.4 An Overall Toxicity Score
As described in Section 2.3, we extracted the proportion of patients in a trial that experience each
individual toxicity at Grade 3 or 4. In this section, we present a methodology for combining these
individual toxicity proportions into a clinically relevant score that captures the overall toxicity of
a treatment.
To gain insight into the rules that clinical decision makers apply in deciding whether a treatment
has an acceptable level of toxicity, we referred to guidelines established in Phase I clinical trials. The
primary goal of these early studies is to assess drugs for safety and tolerability on small populations
and to determine an acceptable dosage level to use in later trials (Golan et al. 2008). These trials
enroll patients at increasing dosage levels until the toxicity becomes unacceptable. The Patients
and Methods sections of Phase I trials specify a set of so-called dose-limiting toxicities (DLTs). If
a patient experiences any one of the toxicities in this set at the specified grade, he or she is said to
have experienced a DLT. When the proportion of patients with a DLT exceeds a pre-determined
2The full survival distributions of all patients were available for only 340/483 (70.4%) of treatment arms, as
opposed to the median which was available for 453/483 (93.8%). Given this limitation as well as the established use
of median survival as a primary endpoint in Phase III trials, we have chosen to proceed with the median.
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Variable AverageValue Range
%
Reported
Patient Demographics
Fraction male 0.72 0.29 – 1.00 97.9
Fraction with prior palliative chemotherapy 0.13 0.00 – 1.00 98.1
Median age (years) 59.6 46 – 80 99.2
Weighted performance status1 0.86 0.11 – 2.00 84.1
Fraction with primary tumor in the stomach 0.90 0.00 – 1.00 94.8
Fraction with primary tumor in the GEJ 0.07 0.00 – 1.00 94.2
Non-drug trial information
Fraction of study authors from each country
(43 different variables)
Country
Dependent 0.00 - 1.00 95.6
2
Fraction of study authors from Asian country 0.43 0.00 – 1.00 95.6
Number of patients 54.4 11 – 521 100.0
Publication year 2003 1979 – 2012 100.0
Trial outcomes
Median overall survival (months) 9.2 1.8 – 22.6 93.8
Incidence of each Grade 3/4 or Grade 4
toxicity –Toxicity Dependent–
1 A composite score of the Eastern Cooperative Oncology Group (ECOG) performance status of patients in a
clinical trial. See Appendix A.1 for details.
2 The remaining studies listed affiliated institutions without linking authors to institutions.
Table 2.1: Non-drug variables extracted from gastric and gastroesophageal cancer clinical trials.
These variables, together with the drug variables, were inputted into a database.
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threshold, the toxicity is considered “too high,” and a lower dose is indicated for future trials. From
these Phase I trials, we can learn the toxicities and grades that trial designers consider the most
clinically relevant, and design a composite toxicity score to represent the fraction of patients with
at least one DLT during treatment.
Based on a review of the 20 clinical trials meeting our inclusion criteria which also presented
a Phase I study (so-called combined Phase I/II trials), we identified the following set of DLTs to
include in calculation of our composite toxicity score (see Appendix A.2 for details):
1. Any Grade 3 or Grade 4 non-blood toxicity, excluding alopecia, nausea, and vomiting.
2. Any Grade 4 blood toxicity.
The threshold for the proportion of patients with a DLT that constitutes an unacceptable level of
toxicity ranges from 33% to 67% over the set of Phase I trials considered, indicating the degree of
variability among decision makers regarding where the threshold should be set for deciding when
a trial is “too toxic.”
The fraction of patients with at least one DLT during treatment cannot be calculated directly
from the individual toxicity proportions reported in Phase II/III clinical trials. For instance, in a
clinical trial in which 20% of patients had Grade 4 neutropenia and 30% of patients had Grade 3/4
diarrhea, the proportion of patients with a DLT might range from 30% to 50%. As a result, there
is a need to combine the individual toxicity proportions into an estimate of the fraction of patients
with a DLT. We evaluated five different methods for performing this combination, and found the
following approach to be the most accurate (see Appendix A.3) :
1. Group the DLT toxicities into the 20 broad anatomical/pathophysiological categories defined
by the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0
(National Cancer Institute 2006).
2. For each trial, assign a “group score” for each group equal to the incidence of the most
frequently occurring DLT in that group.
3. Compute a final toxicity score for the trial by assuming toxicities from each group occur
independently of one another, with probability equal to the group score.
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If one or more of the DLT toxicities for a trial arm are mentioned in the text but their values cannot
be extracted (e.g. if toxicities are not reported by grade), then the overall toxicity score for that
trial is marked as unavailable. This is the case for 106/483 (21.9%) of trial arms in the database.
By taking a maximum over all the reported toxicities in each category, this method has the
advantage of being robust to the uneven reporting of infrequently observed toxicities within each
category. Moreover, it yields a correlation coefficient of 0.893 between the estimated and actual
proportion of patients with any Grade 3/4 toxicity on the 36 trial arms for which this data was
available (Appendix A.3). As a result, we have confidence that our overall toxicity score calculated
in this manner is a reliable indicator of the fraction of patients experiencing a DLT.
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Chapter 3
Statistical Models for Clinical Trials
This section describes the development and testing of statistical models that predict the outcomes of
clinical trials. These models are capable of taking a proposed clinical trial involving chemotherapy
drugs that have been seen previously in different combinations and generating predictions of patient
outcomes. In contrast with meta-analysis and meta-regression of clinical data, whose primary aim
is the synthesis and summary of existing trials, our objective is accurate prediction on unseen future
trials (out-of-sample prediction).
Key components in the development of our predictive models include (i) the definition of vari-
ables that describe a clinical trial, including the patient characteristics, chemotherapy treatment,
and trial outcomes described in Table 2.1, (ii) utilization of statistical learning techniques that limit
model complexity to improve predictability, and (iii) development of a sequential testing framework
to evaluate our models’ out-of-sample prediction accuracy. Details of each of these components and
results follow in the sections below.
3.1 Data and Variables
The data that we extracted from published clinical trials described in Table 2.1 was used to develop
the statistical models. This data can be classified into four categories: patient demographics, non-
drug trial information, the chemotherapy treatment, and trial outcomes.
One challenge of developing statistical models using data from different clinical trials comes
from the patient characteristic data. The patient populations can vary significantly from one trial
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to the next. For instance, some clinical trials enroll healthier patients than others, making it
difficult to determine whether differences in outcomes across trials are actually due to different
treatments or only differences in the patients. To reduce the impact of such confounding variables,
traditional meta-analyses often limit their scope to at most a few dozen reports with similar patient
populations. We consider this reduction in scope an unnecessarily large price to pay for the goal of
ensuring patient homogeneity, and choose instead to include these confounding variables explicitly
in our modeling. In this way, models can be trained on the entirety of historical data, and differences
in the underlying patient populations are automatically accounted for in the model. To this end, we
include in our model all of the patient demographic and non-drug trial variables listed in Table 2.1,
excluding the number of patients in the trial. The reporting frequencies for each of these variables
is given in Table 2.1, and missing values are replaced by their variable means before model building.
For each treatment protocol we also define a set of variables to capture the chemotherapy drugs
used and their dosage schedules. There exists considerable variation in dosage schedules across
chemotherapy trials. For instance, consider two different trials that both use the common drug
fluorouracil1: in the first, it is administered 3, 000mg/m2 once a week, and in the second, at
200mg/m2 once a day. To allow for the possibility that these different schedules might lead to
different survival and toxicity outcomes, we define variables that describe not only whether or not
the drug is used (a binary variable), but we also define variables for both the instantaneous and
average dosages for each drug in a given treatment. The instantaneous dose is defined as the dose
administered in a single session, and the average dose is defined as the average dose delivered each
week.
Lastly, for every clinical trial arm we define outcome variables to be the median overall survival
and the combined toxicity score defined in Section 2.4. Trial arms without an outcome variable are
removed prior to building or testing the corresponding models.
3.2 Statistical Models
We implement and test several statistical learning techniques to develop models that predict clinical
trial outcomes. Information extracted from results of previously published clinical trials serve as
1Lutz et al. (2007) and Thuss-Patience et al. (2005)
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the training database from which the model parameters are learned. Then, given a vector of inputs
corresponding to patient characteristics and chemotherapy treatment variables for a newly proposed
trial, the models will produce predictions of the outcomes for the new trial.
The first class of models we consider are those which assume a linear relationship between the
input variables and the outcomes. If we let x represent a vector of inputs for a proposed trial (i.e.
patient, trial, and treatment variables) and y represent a particular outcome measure we would
like to predict (e.g. median survival), then this class of models assumes a relationship of the form
y = βTx + β0 + , for some unknown vector of coefficients β, intercept β0, and error term . We
assume that the noise terms are independent and identically distributed across trial arms, as tests
on the model residuals have indicated only mild heteroskedasticity of variance (see Appendix A.5).
Ordinary least squares is the classical method for learning the values of the model parameters
β and β0, by minimizing the sum of the squared prediction errors over the training set. However,
it is well known that in settings with a relatively small ratio of data samples to predictor variables,
ordinary least squares produces highly variable estimates of β and β0 that are overfit to the training
set. To overcome this limitation and to handle issues of collinearity between the predictor variables
(see Appendix A.4), we employ two algorithms for estimating β and β0 by minimization of the
following objective:
min
β,β0
N∑
i=1
(βT (xi) + β0 − yi)2 + λ‖β‖p (3.1)
Here, λ is a regularization parameter that limits the complexity of the model and prevents
overfitting to the training data, thereby improving prediction accuracy on future unseen trials. In
building our models, we choose the value of λ through 10-fold cross-validation on the training set.
The choice of norm p leads to two different algorithms. Setting p = 2 yields the more traditional
Ridge Regression algorithm (Hoerl and Kennard 1970), popular historically for its computational
simplicity. More recently the choice of p = 1, known as the Lasso, has gained popularity due to its
tendency to induce sparisty in the solution (Tibshirani 1996). We present results for both variants
below.
The use of regularized linear models provides significant advantages over more sophisticated
models in terms of simplicity, ease of interpretation, and resistance to overfitting. Nevertheless,
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there is a risk that they will miss significant nonlinear effects and interactions in the data. Therefore,
we also implement and test two additional techniques which are better suited to handle nonlinear
relationships: Random Forests and Support Vector Machines.
The Random Forests algorithm makes no underlying assumptions about the relationship be-
tween the input and output variables. The building block for the algorithm is the regression tree
(Breiman et al. 1984), which is generated by recursively partitioning the input space into regions
with similar outputs. When given a new input, a regression tree will produce as a prediction the
average training set output from the corresponding region. Random Forests extends this concept
by introducing randomization to build an ensemble of hundreds of regression trees, and then av-
eraging the predictions made by the individual trees (Breiman 2001). We use the nominal values
recommended by Hastie et al. (2008) for the number of trees to grow (500) and minimum node
size (5). The number of variable candidates at each split is chosen through 10-fold cross-validation
on the training set from among exponentially spaced candidates centered at d/3, where d is the
number of input variables.
Regression trees and therefore Random Forests are naturally able to accomodate nonlinearities
and variable interactions. In addition, they have been shown to have high predictive accuracy on
a number of empirical tests (Caruana and Niculescu-Mizil 2006). Nevertheless, the models and
predictions they produce are not as readily interpretable as those generated by regularized linear
regression.
The final modeling approach we consider is the use of support vector machines (SVM) for
regression. Similar to regularized linear regression, support vector machines use regularization
penalities to limit model complexity and avoid overfitting to the training data. In addition, they
employ the use of kernels to allow for the implicit modeling of nonlinear and even nonparametric
functions. The reader is referred to Vapnik (1998) and Cristianini and Shawe-Taylor (2000) for more
details. While support vector regression offers the ability to model more complex relationships than
a simple linear model, it introduces additional practical challenges, in particular the selection of an
optimal kernel for modeling. Following the approach of Hsu et al. (2003), we adopt the radial basis
function kernel and select the regularization parameter C and kernel parameter γ through 10-fold
cross validation over an exponentially spaced 2-D grid of candidates (C = 2−5, 2−3, . . . , 215, γ =
2−15, 2−13, . . . , 23).
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All models were built and evaluated with the statistical language R version 2.15.3 (R Core Team
2012) using packages glmnet (Friedman et al. 2010), randomForest (Liaw and Wiener 2002), and
e1071 (Meyer et al. 2012).
3.3 Results
Following the methodology of Section 2, we collected and extracted data from a set of 406 pub-
lished journal articles from 1979–2012 describing the treatment methods and patient outcomes for
a total of 483 treatment arms of gastroesophageal cancer clinical trials. Within this set, 72 differ-
ent chemotherapy drugs were used in a wide variety of combinations and dosages, with 19 drugs
appearing in five or more trial arms.
To compare our statistical models and evaluate their ability to predict well on unseen trials, we
implement a sequential testing methodology. We begin by sorting all of the variables extracted from
published clinical trials in order of their publication date. We then only use the data from prior
published trials to predict the patient outcomes for each clinical trial arm. Note that we never use
data from another arm of the same clinical trial to predict any clinical trial arm. This chronological
approach to testing evaluates our model’s capability to do exactly what will be required of it in
practice: predict a future trial outcome using only the data available from the past. Following this
procedure, we develop models to predict the median survival as well as the overall toxicity score.
We begin our sequential testing one third of the way through the set of 483 total treatment arms,
setting aside the first third (161) to use solely for model building. Of the remaining 322 trials, we
predict outcomes only for those using drugs that have been seen at least once in previous trials
(albeit possibly in different combinations and dosages).
The survival models are evaluated by calculating the root mean square error (RMSE) between
the predicted and actual trial outcomes. They are compared against a naive predictor (labeled
“Baseline”), which ignores all trial details and reports the average of previously observed outcomes
as its prediction. Model performance is presented in terms of the coefficient of determination (R2)
of our prediction models relative to this baseline. To illustrate changes in model performance over
time, we calculate the R2 for each model over all test points within a 4-year sliding window. These
are shown in Figure 3-1, along with the values of the RMSE and R2 over the most recent 4-year
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Figure 3-1: [Left] Sequential out-of-sample prediction accuracy of survival models calculated over
4-year sliding windows ending in the date shown, reported as the coefficient of determination (R2)
of our prediction models. Ordinary least squares is not shown because all values are below 0.4.
[Right] Root mean square prediction error (RMSE) and R2 for the most recent 4-year window of
data (March 2008–March 2012), which includes 134 test trial arms.
window of sequential testing.
To evaluate the toxicity models, we recall from the discussion of Section 2.4 that the toxicity
of a treatment is considered manageable as long as the proportion of patients experiencing a dose-
limiting toxicity is less than a fixed threshold – a typical value used in Phase I studies for this
threshold is 0.5. Thus we evaluate our toxicity models on their ability to distinguish between trials
with “high toxicity” (score > 0.5) and those with “low toxicity” (score ≤ 0.5). The metric we
will adopt for this assessment is the area under the receiver-operating-characteristic curve (AUC).
The AUC can be naturally interpreted as the probability that our models will correctly distinguish
between a randomly chosen test trial arm with high toxicity against a randomly chosen test trial
arm with low toxicity. As was the case for survival, we calculate the AUC for each model over a
4-year sliding window, with the results shown in Figure 3-2.
We see in Figures 3-1 and 3-2 that models for survival and toxicity all show a strong trend of
improving predictability over time. This is encouraging, as it indicates our models are becoming
more powerful as additional data is added to the training set. We see that the linear Ridge Regres-
sion and Lasso models perform the strongest in both cases – with model R2 values approaching 0.6
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Figure 3-2: [Left] Sequential out-of-sample classification accuracy of toxicity models calculated over
4-year sliding windows ending in the date shown, reported as the area under the curve (AUC) for
predicting whether a trial will have high toxicity (score > 0.5). [Right] AUC for the most recent
4-year window of data (March 2008–March 2012), which includes 119 test trial arms. Of these,
21/119 (17.6%) actually had high toxicity.
for survival, and AUC values above 0.825 for predicting high toxicity, we have evidence that the
survival and toxicity outcomes for clinical trials can be reasonably well predicted ahead of time, as
long as the drugs have been seen before.
Ordinary (unregularized) least squares performs very poorly at predicting survival, which is
not surprising given its tendency to overfit given the small ratio of predictor variables to training
samples; its stronger performance in predicting toxicity indicates that it still has some ability to
rank treatments in terms of their toxicity (which is what the AUC metric measures). Nevertheless,
it is outperformed by both of the regularized linear models, and there is no reason to pursue it
further. Finally, we note that the performance of the Random Forests algorithm is not competitive
with the regularized linear models in terms of predicting either survival or toxicity.
As a result of this performance assessment, we identified the regularized linear models as the best
candidates for inclusion in our optimization models. They are both the strongest and simplest of
the models we evaluated. Before proceeding, we conducted additional testing to determine whether
the explicit inclusion of pairwise interaction terms between variables improved either of the models
for survival and toxicity in a significant way. We found this not to be the case (see Appendix A.6),
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Figure 3-3: Performance of the Ridge Regression models for survival and toxicity over the most
recent 4 years of data (March 2008–March 2012) [Left] Predicted vs. actual values for survival
model (n = 134). [Right] ROC Curve for high toxicity (score > 0.5) predictions (n = 119), of
which 21 are actually high.
and chose to proceed with the simpler models without interaction terms. Since both the Ridge
Regression and Lasso models show very similar performance, and because the Ridge Regression
model lends itself directly to the computation of a model uncertainty measure (Section 3.4 below)
that we utilize in the design of clinical trials, we selected the Ridge Regression models to carry
forward into the optimization. Depictions of the predicted vs. actual values for survival along with
the receiver-operating-characteristic (ROC) curve for toxicity are shown for the Ridge Regression
models in Figure 3-3.
3.4 Model Uncertainty
We implement data-driven methods for estimating and reporting the level of uncertainty in our
models and their predictions. These methods provide an indication of how confident our models
are in their predictions, helping to guide the design of new clinical trials with promising outcomes
in the presence of uncertainty. We also envision other applications for the confidence estimation
procedure developed here, such as helping determine the number of patients required to test a
particular therapy before its efficacy can be known to a desired degree of accuracy.
The use of linear models allows us to leverage statistical methods for uncertainty characteriza-
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tion that have been developed in this setting. If we denote by X the matrix of input variables in
our training set (rows correspond to trial arms, columns to the demographic and drug variables),
and let Y be a vector of recorded outcome measures for each trial (e.g. median survival), then the
uncertainty in the unregularized least squares estimator βˆU is captured by the covariance matrix
ΣU = σ2(XTX)−1. Here σ2 is the noise variance, for which an estimate s2 can be derived from the
residuals of the model fit. Note that when we refer to the training set here, we mean the training
set up to the moment in time that we are making predictions. We calculate the uncertainty metrics
at each prediction in our sequential approach, so the uncertainties are obtained only using prior
data.
Variances for each of the model coefficients βiU can then be obtained directly from the diagonal
elements of ΣU, and variances for the predictions at a new trial x0 are estimated by (s2+xT0 ΣUx0).
From these quantities confidence intervals can readily be defined, centered at the model estimates.
To adapt these uncertainty estimators to the regularized setting, we use the following equation mo-
tivated by Bishop (2006) as an approximate uncertainty matrix for the regularized Ridge estimator
βˆR:
ΣR = σ2(XTX + λI)−1 (3.2)
From ΣR we similarly obtain uncertainty estimates for each model coefficient, as well as confi-
dence intervals for predictions on new trials. In addition, we can develop estimates of the average
uncertainty in our model associated with each of the individual drugs. Recall that our models
include three variables for each drug used in a trial arm: a binary variable indicating whether the
drug is included, and two variables encoding the dosage. For a given drug i, consider a vector xi
whose only nonzero components are the dosage variables corresponding to drug i; for these elements
we set the binary variable to 1, and the dosage variables to the average dosage administered for
that drug in the training set. Then the effect on the outcome of using drug i at its average dose
has an uncertainty given by:
σ2i = xTi ΣRxi (3.3)
This quantity provides a representation of our model’s uncertainty regarding the effect of each
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drug. In Figure 3-4, we provide two examples of how the model’s uncertainty evolves over time
as new trials are conducted and added to our training database. Shown are the model’s estimates
and confidence intervals for the impact of two different drugs on patient survival. On the left is the
drug Oxaliplatin, first appearing in a clinical trial at the end of 2002 and appearing in 59 trial arms
over the next decade. We see that the two-sigma confidence intervals start out with a wide range of
nearly ten months, reflecting our large initial uncertainty regarding the drug’s efficacy; they then
gradually decrease over time as more trials are added to the model and improve its confidence.
Moreover, as the model’s best estimate of the drug’s efficacy evolves over time, it remains well
within the confidence intervals of prior years. We contrast this behavior with that of the drug
Doxorubicin (right), which appears in 34 trial arms prior to 2004, but in only two trials afterwards.
As the model gains no new information about Doxorubicin over this time period, the estimate and
uncertainty of its efficacy are largely unchanged.
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Figure 3-4: Model estimates over time for the effect of Oxaliplatin (left) and Doxorubicin (right)
on the median patient survival, when considering the average dosages of each drug. Error bars
depict the model’s assessment of its uncertainty (±2σ).
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Chapter 4
Design of Clinical Trials
In this section, we present an analytical approach for designing clinical trials using mixed integer
and robust optimization. Currently, most clinical trials are designed by researchers who test new
therapies in the laboratory and then turn the most promising treatments into clinical trials (Page
and Takimoto 2002, Pratt 1994, Golan et al. 2008). These clinical trials are then sponsored or
funded by a variety of organizations or individuals such as physicians, medical institutions, founda-
tions, pharmaceutical companies and federal agencies (ClinicalTrials.gov 2007). Using the extracted
data and the predictive statistical models we have developed in Sections 2 and 3, we develop an
optimization strategy for designing clinical trials. This would help researchers and organizations
to select the chemotherapy drugs to use in a new clinical trial by using analytical methods to com-
plement laboratory tests. The proposed strategy uses all the known data collected in past trials to
make decisions, which is a key advantage of our approach over current practices. In this section, we
will first describe the mixed integer optimization model that we use. We will then present a robust
version of this model, which helps to control the stability of the predictions. Lastly, we present
some results of the models and compare them to the real selections made by oncologists.
4.1 Model Formulations
Given the current data from clinical trials and the current predictive models that we have con-
structed, we would like to select the next best trial to perform. The determination of the next
“best” trial can be made in different ways. Here, we choose to select the trial that maximizes
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survival and limits toxicity, by using the predictive models presented in Section 3. Our reasoning
for this is that for the majority of Phase III trials in our database, the stated primary objective
was to demonstrate improvement in terms of the median overall survival (OS) of patients in the
treatment group.
To use the predictive models in an optimization problem, we first need to define decision vari-
ables corresponding to the variables in these models. We first fix the patient characteristic variables
described in Table 2.1 to constant values. For overall survival the specific constants do not matter
as they affect all suggested combinations equally. For toxicity, the constants we choose affect the
value of the rhs t we use in the formulations. We can choose values that are representative for a
population of patients or a subpopulation.
We then define decision variables for the chemotherapy variables described in Section 3.1. Sup-
pose there are n possible chemotherapy drugs to select from when designing a clinical trial. We will
assume here that we are trying to select a clinical trial to perform using only existing drugs that
were used in the predictive models (we start including a drug in the predictive models when it has
been seen in at least one previous trial arm). We define three variables for each drug, corresponding
to the chemotherapy treatment variables used in the statistical models: a binary indicator variable
zi to indicate whether drug i is or is not part of the trial (zi = 1 if and only if drug i is part of
the optimal chemotherapy regimen), a continuous variable ui to indicate the instantaneous dose of
drug i that should be administered in a single session, and a continuous variable vi to indicate the
average dose of drug i that should be delivered each week.
We will then use the regularized linear models from Section 3.2 with these decision variables as
inputs. Let the model for overall survival (OS) be denoted by β′(z,u,v), where (z,u,v) denotes
the vector of size 3n, where the first n entries are the binary drug variables z, the second n entries
are the instantaneous dose variables u, and the last n entries are the average dose variables v.
Similarly, we have a model for overall toxicity, which we will denote by τ ′(z,u,v). Note that these
models are all linear in the variables.
We can then select the next best trial to perform by using the following mixed integer opti-
mization model:
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maximize β′(z,u,v) (1)
subject to τ ′(z,u,v) ≤ t, (1a)
n∑
i=1
zi = N, (1b)
Az ≤ b, (1c)
cizi ≤ ui ≤ Cizi, i = 1, . . . , n, (1d)
dizi ≤ vi ≤ Dizi, i = 1, . . . , n, (1e)
(ui, vi) ∈ Ωi, i = 1, . . . , n, (1f)
zi ∈ {0, 1}, i = 1, . . . , n. (1g)
The objective of (1) maximizes the predicted overall survival of the selected chemotherapy regimen.
Constraint (1a) bounds the predicted toxicity by a constant t. This constant values can be defined
based on common values used in Phase I/II trials, or can be varied to suggest trials with a range
of predicted toxicity. In Section 4.4, we present results from varying the toxicity limits. Constraint
(1b) sets the total number of drugs in the selected trial toN , which can be varied to select trials with
different numbers of drugs. We also include constraints (1c) to constrain the drug combinations
that can be selected, which incorporate the generally accepted guidelines for selecting combination
chemotherapy regimens. These guidelines recommend that drugs with different mechanisms of
action be used, which is equivalent in our situation to selecting drugs from different classes (Page
and Takimoto 2002, Pratt 1994, Golan et al. 2008). We capture this guideline by limiting the drug
combination to contain no more than one drug from the classes of drugs used for gastric cancer. The
other guidelines for combination chemotherapy include selecting drugs with different dose limiting
toxicities, and drugs with different patterns of resistance. However, we found in our database
of clinical trials that classes with the same pattern of resistance or with the same dose-limiting
toxicities are often combined. Therefore, we only incorporated guidelines that were violated no
more than once in our database.1
1The following pairs of classes were disallowed from being used together: anthracycline/camptothecin, alkylating
35
The constraints (1c) can also eliminate or force other combinations of drugs, which may be
necessary due to the known toxicities and properties of the drugs. Additionally, these constraints
can be used to add preferences of the business or research group running the clinical trial. For
example, a pharmaceutical company may want to force a new drug they have developed and only
tested a few times to be used in the trial. In this case, the optimal solution will be the best drug
combination containing the necessary drug.
Constraints (1d) give a lower bound ci and a upper bound Ci for each drug’s instantaneous
dose ui, given that the drug i has been selected. These bounds have been defined through Phase I
clinical trials. Constraints (1e) similarly provide upper and lower bounds for each drug’s average
dose vi. Constraints (1f) limit ui and vi to belong to a feasible set Ωi. This is important since
the instantaneous dose and the average dose are often not independent. In the results shown later
in this section, we let Ωi be all combinations of instantaneous and average doses that have been
used in prior clinical trials. This forces the dosage for a particular drug to be realistic. Lastly,
constraints (1g) define z to be a binary vector of decision variables. For the remainder of the thesis,
we will refer to the feasible set of (1), that is the set of all vectors z, u, and v satisfying constraints
(1a)–(1g), as Wˆ.
While the optimization model (1) finds the single best trial to suggest, we are also interested
in building a model to suggest k different trials at once. One reason for this is for recommending
trials when multiple trials will be run at once. We would like to suggest different trials that will
all provide us with interesting information, before knowing the results of each of the other trials.
Additionally, we would also like to see all of the best k trials since there are often several different
drug combinations with similar overall survival predictions, and one is not necessarily superior to
the others. We can thus alter model (1) to propose k different trials. We do this by including
k vectors of binary decision variables, {z1, z2, . . . , zk}, k vectors of instantaneous dose decision
variables, {u1,u2, . . . ,uk}, and k vectors of average dose decision variables, {v1,v2, . . . ,vk}. We
then solve the following problem:
agent/taxane, taxane/topoisomerase II inhibitor, antimetabolite/protein kinase, and camptothecin/topoisomerase II
inhibitor. If a chemoprotectant drug is used, it must be used with a drug from the antimetabolite class that is not
capecitabine.
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maximize
k∑
j=1
β′(zj ,uj ,vj) (2)
subject to (zj ,uj ,vj) ∈ Wˆ, j = 1, . . . , k, (2a)
zj1 6= zj2 , j1 = 1, . . . , k − 1, j2 = j1 + 1, . . . , k. (2b)
The objective of (2) aims to maximize the total survival of the k different trials. Constraints (2a)
require each selected trial meet the constraints of (1). Constraints (2b) prevent any pair of suggested
trials from having identical drugs, and can be implemented using standard techniques; we will not
elaborate further here because in practice our models will be solved using the column generation
approach described in Section 4.3. In the remainder of the thesis, we will refer to all variables
satisfying constraints (2a) and (2b) as the feasible set W. Note that this formulation requires the k
trials to all be different, but they could be very similar. The k trials are only required to have one
different drug between any two trials. We will see in the next section how the trials are encouraged
to be more diverse using robust optimization.
4.2 A Robust Optimization Model
While the models presented in Section 4.1 correctly select the best trials using the predictive
models, the optimal solution can be very sensitive to the coefficients of the regularized linear model
for survival (β). To handle this, we use robust optimization to allow β to vary in an uncertainty
set. As described in Section 3.4, we constructed an uncertainty measure to capture the uncertainty
of each drug. In the following optimization formulation, we allow the binary drug coefficients to
vary in this uncertainty set, while keeping the instantaneous and average dose coefficients fixed.
Denoting the feasible set of (2) by W, we can rewrite (2) as
max
(zj ,uj ,vj)∈W,∀j
k∑
j=1
[(βz)′zj + (βu)′uj + (βv)′vj ] (3)
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We can then reformulate this as the following robust problem:
max
(zj ,uj ,vj)∈W,∀j
min
βz
k∑
j=1
[(βz)′zj + (β¯u)′uj + (β¯v)′vj ] (4)
subject to |β
z
i − β¯zi |
σi
≤ Γ, i = 1, . . . , n, (4a)
n∑
i=1
|βzi − β¯zi |
σi
≤ Γ
√
N, (4b)
where βz is now a vector of variables, and β¯z, β¯u, and β¯v are the coefficient values of the predictive
models that have been constructed for the binary variables, instantaneous dose variables, and
average dose variables, respectively. For each drug i, σi is the uncertainty parameter described
in Section 3.4. The parameter Γ controls how conservative we would like to be. Constraints (4a)
restrict each coefficient βzi to be at most Γσi larger or smaller than the nominal coefficient β¯zi .
Constraint (4b) further restricts the sum of the normalized deviations of βzi from β¯zi to be no more
than Γ
√
N , where N is the number of drugs that can be selected in a single trial. This constraint
prevents the robust model from being too conservative.
For a fixed set of (zj ,uj ,vj) ∈ W, the inner optimization problem selects the worst possible
vector of coefficients βz that is feasible, given the constraints limiting βz to be close to β¯z. The
outer optimization problem then tries to find the best set of trials (zj ,uj ,vj) ∈ W given this
worst case approach. This problem is thus robust in the sense that we are trying to maximize
the worst case scenario in a given uncertainty set. This approach combines Wald’s maximin model
(Wald 1945) with a parameter to control how conservative the solution is, or the price of robustness
(Bertsimas and Sim 2004).
Constraint (4b) also serves to encourage the k trials to be different from each other. If many
drugs are selected, many coefficients will contribute to the objective, and constraint (4b) will prevent
them all from being pushed to their worst case bound. On the contrary, if only a few drugs are
selected, only a few coefficients will contribute to the objective, and constraint (4b) allows all of
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them to be closer to their worst case bound. Evidence of this effect will be shown in the results
section below.
To solve (4), we first reformulate the problem to eliminate all absolute values, using standard
linear optimization techniques (Bertsimas and Tsitsiklis 1997). We then take the dual of the inner
problem, resulting in a mixed integer optimization problem that can be solved as before. Note that
(3) is a special case of the robust problem (4), where Γ is set to zero.
4.3 A Column Generation Approach
The optimization model (4) solves very slowly when asked for even a modest number of suggestions,
due to the symmetry in the formulation of W. Here, we present a fast column generation-based
approach to generate approximate solutions to (4).
Define variables δt associated with each feasible (zt,ut,vt) ∈ Wˆ. Let T be the set of all drug
tuples of size N , and let VR be the set of all feasible treatment indexes of treatments using tuple
R ∈ T . Finally let U be uncertainty set for βz, as defined in (4a) and (4b) above. Then (4) can be
reformulated as:
max
δt
min
βz∈U
∑
t
n∑
i=1
(βzi ztiδt + β¯ui utiδt + β¯vi vtiδt) (5)
subject to
∑
t
δt = k, (5a)
∑
t∈VR
δt ≤ 1, ∀R ∈ T, (5b)
δt ∈ {0, 1}, ∀t. (5c)
Constraint (5a) requires that we select k different treatments, and constraint (5b) prevents us
from selecting more than one treatment with the same set of drugs. As an approximation, we
consider a relaxed version of (5), where constraint (5c) is replaced with 0 ≤ δt ≤ 1. Expanding out
the objective by dualizing the inner problem, we have:
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max
δt,α+,α−,ρ,γ
n∑
i=1
(−β¯zi α+i + β¯zi α−i − Γρi − Γ
√
Nγ) +
∑
t
n∑
i=1
(β¯ui utiδt + β¯vi vtiδt) (6)
subject to σiα+i + σiα−i − ρi − γ ≤ 0, i = 1, . . . , n,
− α+i + α−i =
∑
t
ztiδ
t, i = 1, . . . , n, (i)
∑
t
δt = k, (f)
∑
t∈VR
δt ≤ 1, ∀R ∈ T, (mR)
0 ≤ δt ≤ 1, ∀t,
α+i , α
−
i , ρi ≥ 0, i = 1, . . . n,
γ ≥ 0.
The optimal solution to (6) provides an upper bound on the optimal solution to (5). We solve
(6) by column generation, adding at each iteration the variable δt corresponding to the optimal
solution of the following mixed integer program:
max
z,u,v,s
n∑
i=1
(izi + β¯ui ui + β¯vi vi)− f −
∑
R∈T
sR (7)
subject to (z,u,v) ∈W,
sR ≥ mR[(
∑
i∈R
zi)− (N − 1)], ∀R ∈ T,
sR ≥ 0, ∀R ∈ T.
To obtain a final set of suggestions, we then solve a restricted version of (5), by considering
only the set of δt variables that we have collected through column generation. We require the δt to
be binary, optimally selecting between the current columns. This provides a lower bound on the
optimal solution to the problem, since some of the columns in the true optimal solution might not
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be in the current master problem. This approach allows us to compute a worst-case gap between
approximate solutions to (5) and the optimal solution. Computational experiments show that the
approach yields significant computational improvements over direct approaches to solving (4), with
a limited cost in terms of suboptimality (Appendix A.7).
4.4 Optimization Results
To evaluate the strength of the optimization and predictive models in designing promising clinical
trials, we solve the optimization models sequentially with time, as was done in Section 3.3 with
the prediction models. We start making and evaluating our suggestions one third of the way
through our database of clinical trials, starting in 2002. For all results, we fix the number of
trial recommendations made at any point in time to k = 20. Throughout this section, we will
present results for triplet drug combinations (N = 3). There are several reasons for this. First,
it has been shown in the literature that combination chemotherapy is superior to single drug
treatment (Wagner 2006). This is supported by our database, in which single drug treatments
have a mean overall survival of 6.9 months, compared to a mean overall survival of 10.1 months for
combination chemotherapy. Additionally, nearly 80% of all chemotherapy trials for advanced gastric
and gastroesophageal cancers have tested combined treatments. Since our goal is to recommend
future clinical trials, it is thus logical for us to suggest combination regimens. Additionally, there are
many more potential triplet chemotherapy combinations than doublet chemotherapy combinations,
so our techniques have more to offer in this space. Furthermore, studies have shown a statistically
significant benefit in using triplet regimens compared to doublet regimens (Wagner 2006, Hsu et al.
2012).
We note that evaluating the quality of suggestions made by our optimization model is an
inherently difficult task. If a trial that our models suggest at one point in time is actually performed
in the future, we can of course use the actual outcome of the trial to evaluate our suggestion.
However, given the small number of clinical trials that have been conducted relative to the large
number of feasible drug and dosage combinations, the likelihood of a proposed trial matching an
actual trial performed in the future is small. To address this challenge, we have developed a set of
three metrics to use in evaluating our models over time. Each metric evaluates our models from a
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different perspective, and each comes with its own advantages and limitations. But by considering
all metrics together and comparing our performance on these metrics against the performance of
what we call the “average oncologist,” we provide evidence that our methodology indeed has merit.
We describe and present results for each of these metrics below.
The first metric we define is the Matching Metric, which compares a trial proposal against all
trials that were actually run after the date it was suggested. If the drugs proposed in the trial are
the same as the set of drugs in a trial that was actually performed, we consider it a match. Note
that we do not require the dosages to be identical to consider the trial a match. If a proposed
trial matches one or more future trials, we score the suggestion for survival by taking the average
survival over the set of future trials that it matches. For toxicity, we score the suggestion by the
fraction of matching trials with low toxicity (DLT score below chosen threshold). If a proposed trial
does not match any future trials, it does not get a score. As we slide sequentially through time,
we calculate a score for every trial proposal we make (or no score if there are no future matches)
and record the result. To obtain an overall score for survival and toxicity over the entire evaluation
period (2002 – 2012), we average the scores over all proposals that matched at least one future
trial.
We compare our model’s survival and toxicity scores for the Matching Metric to the baseline
performance of an “average oncologist,” defined as follows. At each point in time, we take the set
of all drug combinations that were actually run in the future, and which could have been suggested
by our optimization model at the time.2 Then, we score each of these combinations using the
same procedure as above (i.e. for survival, average the actual survival of all future trials using
that combination, and for toxicity, record the fraction of future trials that use that combination
with low toxicity), and add them to the evaluation set. To obtain an overall survival and toxicity
score for the “average oncologist,” we then average the scores over all trials in the evaluation set.
The interpretation of this score is that if our “average oncologist” were to randomly select drug
combinations to test out of those which have been actually run in the future, this would be his
or her expected score for the Matching Metric. We present results for the Matching Metric in
Figure 4-1.
2For a trial testing N drugs to be a candidate in the optimization model, all N drugs must have been seen at least
once prior to the evaluation date, and the drug combination must not have been seen previously.
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Figure 4-1: Average scores for Matching Metric for optimization suggestions made from 2002–2012.
Each line corresponds to a different value of the robustness parameter Γ, and the points correspond
to different right-hand-side values t for the toxicity constraint in the set {0.2, 0.3, 0.4, 0.5, 0.6, 0.7}.
There are two parameters that can be adjusted in the optimization model to affect the nature
of the combinations we suggest: the threshold t for the right hand side of the toxicity constraint,
and the robustness parameter Γ. For values of Γ in {0,1,2,3}, the performance of the average
oncologist is dominated by that of the optimization model. In particular, with (Γ = 0, t = 0.5),
the matching trials suggested by the optimization model have average survival that is 3.3 months
greater than the average oncologist, with comparable toxicity. In addition, with (Γ = 0, t = 0.2),
the matching trials suggested by the optimization model have slightly greater survival than the
average oncologist, and no toxicity. These findings are powerful evidence that our methods are
indeed selecting high performing clinical trials before they are being run in practice.
Figure 4-1 shows that the best results for the Matching Metric are achieved at Γ = 0. We note,
however, that strong performance is still observed with nonzero values of Γ, and there are several
reasons why a more conservative decision maker might decide to select a nonzero Γ. First, the
fraction of trials suggested by the optimization that match future trials increases with increasing
Γ, as shown in Table 4.1. A higher match rate might provide a conservative decision maker with
greater confidence that the performance in the future will be as strong as that indicated by the
Matching Metric. Another motivation for the selection of a positive Γ would be to increase the
diversity among the set of proposed trials. For example, if a decision maker has a set of 20 trials to
43
plan over the next two years, he or she may prefer to diversify the trials as much as possible in order
to minimize risk. To quantify the amount of diversity in a set of trials, we can define the distance
between any pair (z1, z2) of 3-drug combinations by d(z1, z2) = 2− (# of drugs in common). Then
for a set of k suggestions, we define the diversity score as the average distance between all pairs.
Average values for the diversity score calculated over the entire evaluation period (2002–2012) are
given in Table 4.1, which shows that diversity increases substantially with increasing values of Γ.
Γ Number of Matches /Number of Suggestions
Average
Diversity Score
0 493 / 6440 (7.7%) .611
1 598 / 6440 (9.3%) .754
2 673 / 6440 (10.5%) .876
3 712 / 6440 (11.1%) .981
Table 4.1: Match rate and average trial diversity as a function of the robustness parameter Γ for a
fixed toxicity right-hand-side t = 0.4.
We have thus far considered average values for the Matching Metric taken over the entire
evaluation period. Additional insight can be obtained by evaluating how the quality of proposed
trials changes over time. To evaluate performance at a fixed time step, we take the set of k = 20
suggestions returned by the optimization model, score them according to the Matching Metric, and
average them to get a score for that time. Similarly, we compute an “average oncologist” score by
averaging the scores for all combinations that could have been recommended by the optimization
at that point. To obtain an upper bound on performance, we calculate the mean of the best m
trials that could have been recommended by the optimization at that point (in terms of overall
survival), where m is the number of optimization suggestions that actually matched. In Figure 4-2,
we present the results for the Matching Metric for survival at (Γ = 0, t = 0.4), and note that similar
trends are observed at other values of Γ and t.
Prior to 2004, the trials suggested by the optimization are not performing as well as those of
the “average oncologist.” They begin improving in 2004, and by 2006 the suggestions made by
optimization are strongly outperforming those made by the average oncologist. This improvement
in performance is not surprising given the improvements we observed in our predictive models over
this same time period, as shown in Section 3.3. We note that the average oncologist score does
show some improvement in outcomes over this period, but the improvement is not as rapid as that
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Figure 4-2: Matching Metric evaluated on optimization suggestions made from 2002–2012 (Γ =
0, t = 0.4). Average actual survival of our optimization suggestions is compared to the best possible
score and an average oncologist baseline.
shown by the optimization model. It is also important to point out that the apparent drop-off in
performance at the end of the evaluation window is an artifact that can be attributed to the small
number of “future trials” in our database that can be matched against after this point in time.
The strength of the Matching Metric is that it directly evaluates the output of our optimization
model using real future trial data, when such an evaluation is possible. Unfortunately, it has three
limitations: (1) it does not capture the regret of not suggesting trials which are actually run in
the future and turn out to be promising, (2) it cannot evaluate the quality of suggestions which
have not been run in the future, which as discussed above can be a significant fraction of our
suggestions, and (3) it does not take the dosages of our suggested combinations into account. We
will address each of these limitations by defining two additional performance metrics, beginning
with the Ranking Metric. The motivation behind the Ranking Metric is to assess how well our
models can identify the top performing trials out of all those which have actually been run in the
future. To calculate the metric, we begin by taking the set of all clinical trials that were actually
run after a fixed evaluation date, and which could have been suggested by our optimization model
on that date. Then, we use our predictive models built with the data prior to the evaluation date
to rank the treatments in order of their expected outcomes. Finally, we calculate our score for
the Ranking Metric by taking the top quartile of the treatments on our ranked list, and averaging
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their true outcomes. Our performance on the Ranking Metric can again be compared against two
baseline scores: the “best possible” score, obtained by ranking the treatments in order of actual
outcomes and then computing the average of the top quartile, and the “average oncologist” score,
calculated as a mean over all treatments on the list. The interpretation of this score is that if
our “average oncologist” were to randomly order the list of all trials that are actually seen in the
future, this would be his or her expected score. The Ranking Metric is shown on the left in Figure
4-3. Again the drop-off in performance of the Ranking Metric at the end is attributed to the small
number of future trials that can be evaluated at this time.
Neither the Matching nor the Ranking metrics can evaluate the quality of our suggestions that
have not been run in the future. This is undoubtedly the most difficult assessment to make, because
we cannot conduct actual clinical trials using all these suggestions. As a result, we turn to the only
measure of performance that we have available: how well do these suggested trials perform, when
evaluated using the final March 2012 regression model trained on the full data set. We call this
metric the Final Model Metric. We feel this metric is important as it is the only one capable of
evaluating trial suggestions that have not yet been run in the future. To calculate the performance
for this metric we take the set of k suggestions made by our optimization model, use the final
regression model to estimate their true outcomes, and average the results. There are three baseline
scores to compare against for this metric: (1) the “best possible” score, calculated by solving
optimization problem (4) using only the drugs and dosages that were known to the model at the
evaluation date, but by taking the model coefficients from the March 2012 regression model and
using Γ = 0, (2) the “random trial” score, calculated by taking all the feasible drug combinations
that could have been suggested, evaluating them using the final model, and averaging the results,
and (3) the “average oncologist” score, calculated by taking all drug combinations that could have
been suggested and were actually run in the future, evaluating them using the final model, and
averaging the results. The Final Model Metric is shown on the right in Figure 4-3. For all metrics,
the performance of the optimization model starts out weak, but improves rapidly over the course
of the 10-year evaluation period.
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Figure 4-3: Ranking Metric (left) and Final Model Metric (right) evaluations of optimization
suggestions made from 2002–2012 (Γ = 0, t = 0.4).
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Chapter 5
Additional Modeling Applications
In this section, we describe two additional applications of our modeling approach that we feel
positively contribute to the design of clinical trials. These are just two of many possible ways our
models could be used to assist clinical trial decision makers.
5.1 Identifying Clinical Trials that are Unlikely to Succeed
A natural application of the statistical models developed in Section 3 involves determining whether
a proposed clinical trial is likely to meet its clinical goals. This is a challenging problem in general,
because of the difficulty of predicting clinical trial outcomes, making our models useful for decision
makers faced with deciding whether to fund a proposed clinical trial. Avoiding trials that are
unlikely to succeed could be beneficial not only to clinical decision makers, who stand to save
significant resources, but also to patients.
To determine if our models can be used to identify trials that are unpromising, we performed
an out-of-sample experiment in which we predicted the median overall survival of each trial before
it was run, based on all previous trial outcomes. Using this prediction along with the computed
standard error σ2i described in Section 3.4, we calculated the probability that the current trial’s me-
dian overall survival exceeds the 5-year rolling average median overall survival. In our experiment,
the decision maker uses these results to avoid the trials with the lowest probability of achieving the
rolling average overall survival.
In Table 5.1, we see that the proposed model is effective at identifying trials that are unlikely
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to outperform recent trials. The 10 trials flagged as least likely to succeed all underperformed the
rolling average, and of the 30 least likely to succeed, 22 did not achieve the mean, 6 were above
average but not in the fourth quartile for survival, and 2 were in the top quartile of recent trials.
Number
Flagged
Below Average
(<50%)
Above Average
(50%-75%)
High
(>75%)
10 10 0 0
20 15 4 1
30 22 6 2
40 30 8 2
50 38 8 4
60 45 11 4
Table 5.1: Out-of-sample accuracy in identifying unpromising trials before they are performed.
Though the decision maker in this experiment is simplistic, ranking trials without regard for
their demographics or their toxicity outcomes, our models for predicting clinical trial outcomes can
be used in much more sophisticated analyses, as well.
5.2 Determining the Best Chemotherapy Treatments to Date
Identifying the best chemotherapy regimen currently available for advanced gastric cancer is a
task that has proven challenging for traditional meta-analysis, but it is one that our methods are
well suited to address. Through the use of regression models, which leverage a large database of
clinical trial outcomes, we are able to control for differences in demographics and other factors
across different clinical trials, enabling direct comparison of results that were not from the same
randomized experiment.
To determine the best chemotherapy treatments to date, we first note that selecting a chemother-
apy treatment for cancer involves a tradeoff between survival time and toxic effects that affect
quality of life. Since individual patients will differ in how they value these competing objectives,
the notion of trying to find the a single “best” regimen is not correct. Instead, we seek the set of
treatments that make up the “efficient frontier” of chemotherapy treatments for a given cancer: a
particular treatment is included in the efficient frontier only if there are no other available treat-
ments with both higher survival and lower toxicity. On the left panel of Figure 5-1, we present the
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survival and toxicity of all large trial arms in our database (with the number of patients exceeding
the mean of 54.4) for which both outcome variables are available, and highlight those that make
up the efficient frontier. A significant concern with this representation is that the demographics of
the patient populations differ from one trial to the next, making a direct comparison between them
difficult. To control for this effect, we utilize the coefficients from the Ridge Regression models for
survival and toxicity trained on the entire data set, which are available at the conclusion of the
sequential testing performed in Section 3.3. To give an example, the fraction of patients with prior
palliative chemotherapy has a regression coefficient βi of −0.70 months in the survival model. A
trial with 80% prior palliative chemotherapy, instead of the population average of 13% (from Table
2.1), would be expected to have −0.70 ∗ (0.13− 0.80) = 0.47 months lower survival. We correct for
this effect by adding 0.47 months to the survival outcome of this trial. After adjusting the survival
and toxicity values for all demographic variables in this manner, we present an updated efficient
frontier in the right panel of Figure 5-1.
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Figure 5-1: Survival and dose-limiting toxicity for clinical trial arms with ≥ 55 patients, before
(left) and after (right) adjustment for demographic factors. After adjustment, the efficient frontier
changes significantly, showing the importance of controlling for demographics when identifying the
best available cancer treatments.
In Table 5.2, we report the treatments (as reported in the papers listed) that are in the efficient
frontier between overall survival and toxicity with and without adjusting for patient demographics
and trial information listed in Table 2.1. We see that the efficient frontier changes considerably when
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Unadjusted Adjusted
Trial Arm Survival(months)
Toxicity
(fraction) EF
Survival
(months)
Toxicity
(fraction) EF
(A) Adelstein et al. (2012) 5.5 .000 Yes 5.5 .000 Yes
(B) Kondo et al. (2000), 5’-DFUR 7.3 .018 Yes 7.4 .043 No
(C) Graziano et al. (2003) 8.6 .020 Yes 7.7 .086 No
(D) Wang et al. (2011) 14.3 .034 Yes 13.7 .181 Yes
(E) Iwase et al. (2011) 15.0 .079 Yes 12.3 .034 Yes
(F) Lorenzen et al. (2007) 17.9 .435 Yes 16.2 .357 Yes
(G) Koizumi et al. (2011) 18.5 .520 Yes 16.0 .485 No
Table 5.2: Trials on the efficient frontier (EF) trading off survival and toxicity, before and after
adjusting for demographics.
adjustments are made for the trial’s demographics — only four of the seven combinations appearing
in the adjusted frontier appeared in the unadjusted frontier, and with significantly reduced median
overall survival times. This indicates that trials often have better outcomes due to the patient
population, and that the outcomes should be adjusted when deciding which treatments are best.
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Chapter 6
Concluding Remarks
We believe that our analytics-based approach has the potential to fundamentally change the design
process for new chemotherapy clinical trials. This approach can help medical researchers identify the
most promising drug combinations for treating different forms of cancer by drawing on previously
published clinical trials. This would save researchers’ time and effort by identifying proposed clinical
trials that are unlikely to succeed and, most importantly, save and improve the quality of patients’
lives by improving the quality of available chemotherapy regimens.
The models presented to predict survival and toxicity given demographic information and
chemotherapy drugs and dosages represents the first application of data mining techniques to pre-
dicting chemotherapy clinical trial outcomes. Our modeling results show that we can predict future
clinical trial outcomes using past data, even if the exact combination of drugs being predicted has
never been tested in a clinical trial before. The optimization models we proposed will open new
frontiers in the design of clinical trials, enabling us to generate new suggestions for clinical trials
instead of being limited to providing predictions of the effectiveness of proposed trials.
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Appendix A
Appendices
A.1 Weighted Performance Status
Performance status is a measure of an individual’s overall quality of life and well-being. It is
reported in our database of clinical trials predominantly using the Eastern Cooperative Oncology
Group (ECOG) scale (Oken et al. 1982), and less often using the Karnofsky performance status
(KPS) scale (Karnofsky 1949). Table A.1 provides counts of how often the different scales are used
in our gastric cancer database.
Scale # Trial Arms
ECOG 414/483 (85.7%)
KPS 68/483 (14.1%)
None 1/483 (0.2%)
Table A.1: Scales used to report performance status in the gastric cancer database.
The ECOG scale runs from 0–5 and is reproduced in Table A.2 for reference. In our database,
patients with ECOG score ≥3 are rare; nearly 90% of the trial arms have no patients with scores in
this range. As a result, we develop a weighted performance status score truncated at 2 as follows:
if p0, p1 and p≥2 are the proportions of patients in the trial with ECOG scores of 0, 1, and at least
2, respectively, then our weighted performance status variable is given by p1 + 2p≥2.
Of the 414 trial arms that report using ECOG score, only 295 arms report the fraction of
patients with each individual score. Of the remaining 119, 15 of these arms report only summary
statistics on the ECOG distribution over the patients (min/max/median), and for these arms we
55
Score ECOG
0 Fully active, able to carry on all pre-disease performance without restriction.
1 Restricted in physically strenuous activity but ambulatory and able to carry
out work of a light or sedentary nature, e.g., light house work, office work.
2 Ambulatory and capable of all selfcare but unable to carry out any work
activities. Up and about more than 50% of waking hours.
3 Capable of only limited selfcare, confined to bed or chair more than 50% of
waking hours.
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed
or chair.
5 Dead.
Table A.2: Eastern Cooperative Oncology Group (ECOG) performance status scale.
do not compute a score. The remaining 104 arms provide a bucketed ECOG breakdown. For
example, 92 arms only report the proportion of patients with either ECOG score 0 or 1, but not
the proportions in each category separately. To compute the weighted performance score for these
arms, we first obtain a rough estimate the proportion of patients with ECOG score 0 and score 1,
based on the proportion of patients in the combined 0-1 bucket. This estimation is done by taking
the n = 292 trials with full ECOG breakdown and nonzero p0 + p1, and fitting a linear regression
model to estimate p0/(p0 + p1) from the logit of p0 + p1 (Figure A-1).
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Figure A-1: Data and resulting model used to split the combined ECOG-01 bucket into the pro-
portion of patients with score either 0 or 1 (n = 292). Model fit by linear regression to the logit of
p0 + p1.
Using this model to split the combined ECOG-01 bucket, we can compute a weighted perfor-
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mance status score for 390/414 of the arms that use the ECOG scale. For the remaining arms
(those with only min/max/median reporting or more complex bucketing), the score is marked as
unavailable.
Of the 68 trial arms that report using the KPS score, 16/68 provide a full KPS breakdown, 30/68
provide a bucketed breakdown, and 22/68 provide only the min/max/median summary statistics.
For the 16/68 arms with full breakdown, we first perform a conversion from the KPS scale to the
ECOG scale based on data in (Buccheri et al. 1996), and then calculate the weighted score as
before. For trial arms reporting only bucketed KPS or summary statistics, the score is marked as
unavailable.
At the end of processing, 406/483 (84.1%) of all trial arms are assigned a weighted performance
status score, with the remaining arms marked as missing a score.
A.2 Definition of Dose-Limiting Toxicity
We reviewed the 20 clinical trials meeting our inclusion criteria which also presented a Phase I
study (so-called combined Phase I/II trials), to learn:
• Which toxicities are considered dose-limiting toxicities (DLTs), and at which grades?
• What fraction of patients must experience one or more of the DLTs for the trial to be con-
sidered “too toxic” (i.e. maximum tolerated dose (MTD) reached)?
18 of 20 trials stated that all Grade 3/4 non-blood toxicities are DLTs, except for some specified
toxicities. These excluded toxicities are:
• Alopecia, 18/18 (100%).
• Nausea/vomiting, 12/18 (67%)
• Anorexia, 5/18 (28%)
• Fatigue, 3/18 (17%)
• Diarrhea, 2/18 (11%)
• Abdominal pain, 1/18 (6%)
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The remaining two papers defined non-blood toxicities considered DLTs as Grade 3/4 stomatitis
and diarrhea. Based on these results, we defined all Grade 3/4 non-blood toxicities except alopecia,
nausea, and vomiting to be dose-limiting toxicities.
In this work, we define all Grade 4 blood toxicities as being a DLT. This is in line with the
Phase I/II trial results, in which 17/20 trials defined Grade 4 Neutropenia as a DLT, 16/20 defined
Grade 4 Thrombocytopenia as a DLT, 7/20 defined Grade 4 Leukopenia as a DLT, and 4/20 defined
Grade 4 Anemia as a DLT. Only one trial defined Grade 3 blood toxicities as DLTs, so we chose to
exclude this level of blood toxicity from our definition of DLT.
19 of the studies specified the proportion of patients experiencing a DLT that would be defined
as the MTD. The studies defined a number of cutoffs:
• 33%: 8/19 (42%)
• 50%: 8/19 (42%)
• 67%: 2/19 (11%)
• 63%: 1/19 (5%)
A.3 Models for Combining Individual Toxicity Levels into an Over-
all Toxicity Level
Here we compare approaches for combining the proportion of patients experiencing individual dose-
limiting toxicities (DLT) into an estimate of the proportion of patients experiencing at least one
DLT. We consider five options for combining the toxicities:
• Max Approach: Label a trial’s toxicity as the proportion of patients with the most fre-
quently occurring DLT. This is a lower bound on the true proportion of patients with a
DLT.
• Independent Approach: Assume all DLTs in a trial occurred independently of one another,
and use this to compute the expected proportion of patients with any DLTs.
• Sum Approach: Label a trial’s toxicity as the sum of the proportion of patients with each
DLT. This is an upper bound on the true proportion of patients with a DLT.
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• Grouped Independent Approach: Define groups of toxicities, and assign each one a
“group score” that is the incidence of the most frequently occurring DLT in that group.
Then, compute a toxicity score for the trial by assuming toxicities from each group occur
independently, with probability equal to the group score.
• Grouped Sum Approach: Using the same groupings, compute a toxicity score for the trial
as the sum of the group scores.
For the grouped approaches, we use the 20 broad anatomical/pathophysiological categories defined
by the NCI-CTCAE v3 toxicity reporting criteria as the groupings.
To compare these approaches, we evaluate how each of these five approaches do at estimating
the proportion of patients with Grade 3/4 toxicities in clinical trials that report this value given the
individual Grade 3/4 toxicities. Because there is a strong similarity between the set of Grade 3/4
toxicities and the set of DLTs, we believe this metric is a good approximation of how well the five
approaches will approximate the proportion of patients with a DLT. 40/482 (8.3%) of trials report
this value, though we can only compute the combined metric for 36/40 (90%) due to missing toxicity
data. The quality of each combination approach is obtained by taking the correlation between that
approach’s results and the combined grade 3/4 toxicities.
Combination Approach Correlation
Grouped Independent 0.893
Independent 0.875
Max 0.867
Grouped Sum 0.843
Sum 0.813
Table A.3: Coefficient of correlation between estimated and actual proportion of patients with a
Grade 3/4 toxicity for various toxicity combination approaches (n = 36).
As seen in Table A.3, all five combination approaches provide reasonable estimates for the
combined toxicity value, though in general grouped metrics outperformed non-grouped metrics.
The best approach is the “grouped independent approach,” because it allows the best approximation
of the combined Grade 3/4 toxicities.
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A.4 Multicollinearity
In this section, we analyze the amount of collinearity between our explanatory variables. In standard
linear regression, a high degree of correlation among the variables can lead to inflated estimation
errors in the model coefficients and poor out-of-sample predictions. It is partially for this reason that
we employ regularization techniques (Ridge Regression and Lasso), which can alleviate the impact
of collinearity on coefficient errors and improve predictability in this setting (see, for example, the
discussion in Hastie et al. (2008), p.61–79). Nevertheless, we acknowledge that the interpretability
of the model coefficients can be impaired by severe collinearity, and we include this section as a
caution to the reader attempting to interpret any of the model coefficients directly.
We first note that the pairwise correlations between the three dosage variables defined for each
drug – binary, average, and instantaneous dose – are all high (in all cases, the correlation coefficient
exceeds 0.65). This is primarily due to the fact that these variables have a large number of rows for
which all values are zero, corresponding to trial arms in which the drugs are not used. In addition
to applying regularization techniques, we have taken two additional steps to limit the impact that
this correlation has on our optimization models:
1. Constructing a single uncertainty score for each drug, avoiding any attempt to interpret the
individual dosage variable standard errors directly.
2. Restricting the optimization to the set of drug dosages that have been observed previously,
so that they have the same general correlation structure as data used to train the model.
While we feel these steps are sufficient to handle the collinearity among the dose variables for
the purposes of our optimization models, care must be taken when attempting to interpret the
individual model coefficients.
We next consider the pairwise correlation coefficients between the remaining variable pairs. We
report any pairs of variables for which the magnitude of the correlation coefficient exceeds 0.5 in
Table A.4. We note that correlations between between different drugs are not problematic from
the standpoint of our optimization, since we impose constraints on the pairs of drugs that can be
selected for our trials. For example, in Table A.4 we see that Leucovorin use is correlated with
that of Fluorouracil. Indeed, Leucovorin is in the class of drugs known as chemoprotectants, which
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are typically paired with drugs in the antimetaboline class, which includes Fluorouracil. Since this
constraint is imposed directly in our optimization, we are able to mitigate the effect of correlation
between these variables. In addition, correlations between non-drug variables do not affect the
optimization, since we are not optimizing over these variables. We note finally that none of the
correlations between a drug and non-drug variable exceeded 0.5.
Category Variable 1 Variable 2 Correlationcoefficient
Variables
from
different
drugs
Leucovorin binary dose Fluorouracil instantaneous dose 0.583
PALA binary dose IFN average dose 0.564
PALA instantaneous dose IFN average dose 0.564
IFN average dose PALA average dose 0.564
Fluorouracil binary dose Leucovorin binary dose 0.563
Fluorouracil instantaneous dose Leucovorin instantaneous dose 0.557
Non-drug
variables
Trial in Asia Trial in South Korea 0.569
Trial in Asia Trial in Japan 0.512
Cancer in stomach Cancer in GEJ -0.919
Table A.4: Pairs of predictor variables with correlation coefficient exceeding 0.5, excluding pairs
corresponding to dosage variables for the same drug.
A.5 Heteroskedasticity
To assess our models for heteroskedasticity of variance, we plot the sequential out-of-sample pre-
diction errors against the parameters of interest to check whether there is a significant trend. In
Figure A-2, we depict the absolute value of the sequential prediction errors for the Ridge Regression
survival and toxicity models against two parameters: the number of patients in the test trial (on
a log-scale to get meaningful separation between the data points), and the predicted value for the
test trial.
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Figure A-2: Heteroskedasticity tests for survival model (top) and toxicity model (bottom). For
both models we check the relationship between the sequential out-of-sample error terms and the
number of patients in the trial arm (left), and the predicted outcome value (right). On top of all
plots we have added a locally linear LOESS smoother (Cleveland et al. 1992) to show the trend.
To quantify magnitude of heteroskedasticity, we calculate how much the errors vary over the
range of our data points, by taking the ratio of the maximum and minimum values from the LOESS
curves shown in Figure A-2. These values are given in Table A.5.
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Model Number of Patients Predicted Value
Survival 2.13 2.50
Toxicity 1.31 1.67
Table A.5: Measure of how much the error variance changes as a function of two parameters: the
number of patients in a trial arm and the predicted outcome value. Heteroskedasticity factors are
calculated as the ratio between the maximum and minimum error values obtained from the LOESS
curves shown in Figure A-2.
According to Fox (1991), heteroskedasticity is only worth correcting if the error terms vary by
more than a factor of 3 over the data set. We conclude that this is not the case for either our
survival or toxicity models, and that heteroskedasticity of variance is mild.
A.6 Interaction Terms
In this section, we test whether the inclusion of interaction terms between our predictor variables
improves the out-of-sample accuracy of our linear models for survival and toxicity. We note that
Random Forests and SVM with a radial basis function kernel naturally capture interactions between
all variables in the model, and there is no need to explicitly define additional interaction variables.
As a result, our focus here will be restricted to the regularized linear models: Ridge Regression and
the Lasso.
We evaluate two classes of interaction terms separately. First, we consider the interactions
between pairs of drugs, which we can account for in our model by adding pairwise products between
all of the binary drug variables in our database. Each of the new binary variables represents a
different drug pair, and will be set to 1 if and only if that drug pair is used in the treatment arm.
There are 72 total drugs in our database, yielding 2,556 possible drug pairs. Of these, only 149 drug
pairs appear in one or more treatment arms in our database. To limit the number of uninformative
variables added to the model, we impose the additional requirement that a drug pair must appear
in at least 3 arms of the database before encoding it with a variable. There are 62 drug pairs
meeting this requirement, so we add these 62 binary drug pair variables to our model.
Next, we consider the interactions between drug variables and the non-drug variables (patient
demographics, as well as non-drug trial information). We model these interactions by taking prod-
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ucts between the binary drug variables and each of the non-drug variables. We again impose the
constraint that an interaction variable must take a nonzero value for at 3 arms of the database
before it will be included in the model. The result is the addition of 289 variables to the model.
In Table A.6, we compare the sequential model performance with and without each set of inter-
action variables. We see that the drug/drug interaction terms provide a very slight improvement
in the survival predictions, but the improvement to the R2 is less than 0.01 for both the Lasso and
Ridge models. The toxicity predictions are slightly degraded by the inclusion of these variables
terms, but again the effect is small. The inclusion of interactions between the drug and non-drug
variables decreases the predictive accuracy of all survival and toxicity models.
No Interactions Drug / Drug Drug / Non-drug
Models Survival
R2
Toxicity
AUC
Survival
R2
Toxicity
AUC
Survival
R2
Toxicity
AUC
Ridge .589 .828 .596 .822 .582 .826
Lasso .600 .836 .605 .824 .584 .819
Table A.6: Performance of the Ridge and Lasso models for survival and toxicity over the most
recent 4 years of data (March 2008–March 2012), with and without the inclusion of interaction
terms. Survival performance is presented in terms of the coefficient of determination (R2) of our
prediction models relative to the baseline, and toxicity performance is reported as the area under
the curve (AUC) for predicting whether a trial will have high toxicity (score > 0.5).
A.7 Computational Experiments on the Column Generation Ap-
proach
To evaluate the efficiency and solution quality of the column generation approach (6), we solved the
model at the beginning of 2010 for tuple size N = 3 and a range of suggestion counts k and robust-
ness parameters Γ. Results were compared with a mixed integer programming formulation of (4).
Experiments were run on an Intel Core i7-860 (2.8 GHz) with 16 GB RAM, and a computational
limit of 30 minutes was applied for each model.
Results are given in Table A.7. Internally calculated optimality gaps (labeled “procedure gaps”
in the table) for the column generation approach were uniformly small, and runtimes dominated
those of the direct MIP formulation of (4) for moderate and large values of k. When possible to
verify, the column generation approach returned optimal solutions to the problem.
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Column Generation Direct MIP
k Γ Runtime ProcedureGap (%)
Opt.
Gap (%) Runtime
Procedure
Gap (%)
Opt.
Gap (%)
5 0 0.51 0 0 14.26 0 0
5 1 0.49 0 0 18.75 0 0
5 2 0.49 0.067 0 15.37 0 0
5 3 0.60 0.269 0 17.82 0 0
10 0 1.25 0 0 > 1800 3.305 0
10 1 1.33 0 0 > 1800 4.587 0
10 2 1.39 0 0 > 1800 5.171 0
10 3 1.78 0.091 n/a > 1800 4.872 n/a
20 0 3.00 0 0 > 1800 14.046 1.542
20 1 2.84 0 0 > 1800 12.688 0.825
20 2 3.19 0 0 > 1800 12.186 0.400
20 3 3.72 0 0 > 1800 12.772 0.832
Table A.7: Computational results for the column generation and direct MIP approaches for tuple
size N = 3, at a range of suggestion counts k and robustness parameters Γ. Runtimes are in
seconds. Procedure gaps are calculated internally for each algorithm between the best solution
and internal upper bound. Optimality gaps are between the algorithm solution and true optimal
solution, when possible to verify (otherwise labeled n/a).
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